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Summary
p27Kip1 and p21Cip1 are thought to suppress tumor growth and prevent cell cycle progression by inhibiting Cdk2-cyclin
E/A kinases. Since Cdk2 is dispensable for mitotic cell division, we analyzed the activity of these inhibitors in Cdk2-
deficient cells. Ectopic expression of p27Kip1 or p21Cip1 efficiently inhibits cell cycle progression of Cdk2−/− fibroblasts.
Loss of p27Kip1 or p21Cip1 confers similar proliferative advantages to Cdk2+/+ and Cdk2−/− cells. Moreover, Cdk2 is dispens-
able for p21Cip1-induced cell cycle arrest after DNA damage. Finally, ablation of Cdk2 in p27Kip1 null mice does not sup-
press their phenotypic defects, including development of pituitary tumors. These results indicate that Cdk2 is not an
essential target for p27Kip1 and p21Cip1 in cell cycle inhibition and tumor suppression.S I G N I F I C A N C E
Controlled synthesis and degradation of the cell cycle inhibitor p27Kip1 are key events in regulating cell cycle progression. It is
generally accepted that p27Kip1, and the related p21Cip1 inhibitor, block the cell cycle by inhibiting the kinase activity of Cdk2-
cyclin E/A complexes. Here, we provide genetic evidence that Cdk2 is dispensable for the inhibitory activity of p27Kip1 and p21Cip1
during the G1 phase of the cell cycle and for their tumor-suppressing properties. Whereas the precise mechanisms by which p27Kip1
and p21Cip1 block cell cycle progression remain to be defined, our findings suggest either that Cdk2 does not mediate the activity
of these inhibitors or, alternatively, that cells possess compensatory mechanisms that efficiently bypass their requirement for Cdk2.Introduction
Coordinated regulation of cell cycle progression is essential for
normal development and homeostasis. Two families of cell cy-
cle inhibitors play vital roles in this process (reviewed in Sherr
and Roberts, 1999). The INK4 protein family specifically binds
to Cdk4 and Cdk6 to inhibit interaction with their activating
subunits, the D type cyclins. On the other hand, the Cip/Kip
family of proteins, p21Cip1, p27Kip1, and p57Kip2, form inactive
complexes with Cdk2-cyclin E and Cdk2-cyclin A. p21Cip1 and
p27Kip1 also bind to Cdk4/6-cyclin D complexes but do not
interfere with their kinase activity, at least under stochiometric
conditions (Blain et al., 1997; LaBaer et al., 1997). Indeed,
these cell cycle inhibitors contribute to the formation of stable
Cdk4/6-cyclin D complexes during the early phases of the cell
cycle (Blain et al., 1997; LaBaer et al., 1997; Cheng et al.,
1999). More recently, the possibility that p21Cip1 and p27Kip1
may have additional roles outside the nucleus is receiving
increasing attention (reviewed in Denicourt and Dowdy, 2004).
In spite of their similar mechanism of action, p21Cip1 and
p27Kip1 play distinct biological roles within the cell. p21Cip1 is
a transcriptional target of p53 and it is believed to be one of
the main effectors of p53-mediated cell cycle arrest (reviewed
in Nakayama and Nakayama, 1998; Sherr and Roberts, 1999).
In contrast, p27Kip1 appears to be a primary negative regulatorCANCER CELL : JUNE 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.during normal cell proliferation in a variety of cell types (Sherr
and Roberts, 1999). Expression of p27Kip1 is controlled by the
forkhead family of transcription factors, a group of downstream
effectors of the PI3Kinase/Akt signal transduction pathway
(Collado et al., 2000). Moreover, p21Cip1 and p27Kip1 differ at
their carboxy-terminus, a domain that provides them with spe-
cific functions (Nakayama and Nakayama, 1998; Sherr and
Roberts, 1999). For instance, p21Cip1 uses this domain to bind
to the proliferating-cell nuclear antigen (PCNA), a DNA poly-
merase delta processivity factor, thus preventing DNA replica-
tion (Chen et al., 1995; Waga et al., 1994; Li et al., 1994; Luo
et al., 1995).
Targeted deletion of p21Cip1 in mice does not cause major
phenotypic abnormalities. However, p21Cip1-deficient mice de-
velop a variety of tumors, albeit with long latencies (Martín-
Caballero et al., 2001). Moreover, p21Cip1−/− cells are signifi-
cantly deficient in their ability to arrest in G1 in response to
DNA damage (Brugarolas et al., 1995; Deng et al., 1995). Abla-
tion of p27Kip1 in mice results in hyperplasia leading to general-
ized organomegaly and increased body size. Moreover, these
animals develop retinal dysplasia and pituitary tumors of the
intermediate lobe (Nakayama et al., 1996; Kiyokawa et al.,
1996; Fero et al., 1996). p27Kip1 heterozygous mice are more
susceptible to radiation- or ENU-induced tumors. None of
these tumors loses its wild-type allele, indicating that p27Kip1DOI 10.1016/j.ccr.2005.05.006 591
A R T I C L Eis haploinsufficient for tumor suppression (Fero et al., 1998).
Cultured cells derived from p27Kip1−/− mice show partial mito-
gen independence (Nakayama et al., 1996; Kiyokawa et al.,
1996; Fero et al., 1996). In human tumors, the levels of p21Cip1
expression are not frequently altered. Yet, p21Cip1 expression
cannot be induced in those tumors that do not express an
active p53 tumor suppressor. The locus encoding p27Kip1 is
also not mutated in most human tumors. However, the levels
of p27Kip1 protein are frequently compromised in a variety of
tumor types. This phenotype often correlates with increased
tumor aggressiveness and poor prognosis (reviewed in Bloom
and Pagano, 2003; Blain et al., 2003).
The observation that Cip/Kip inhibitors stabilize Cdk4/6-
cyclin D complexes (Blain et al., 1997; LaBaer et al., 1997;
Cheng et al., 1999) has led to the proposal that Cdk4/6-cyclin
D kinases may contribute to cell cycle progression by seques-
tering Cip/Kip inhibitors away from other Cdks, mainly Cdk2.
Decreased levels of p27Kip1 would generate sufficient amounts
of active Cdk2-cyclin E complexes to phosphorylate p27Kip1, a
signal required for its degradation by the SCF-Skp2 protea-
some (reviewed in Reed, 2003). Once most of p27Kip1 has been
removed, fully active Cdk2-cyclin E complexes would be avail-
able to completely phosphorylate the Rb protein family, thus
allowing cells to progress from the G1 to the S phase of the
cell cycle (Sherr and Roberts, 1999; Reed 2003).
However, the central role attributed to Cdk2 in cell cycle pro-
gression has been recently challenged by the observation that
mice lacking this kinase develop normally (Ortega et al., 2003;
Berthet et al., 2003). Moreover, Cdk2-deficient cells proliferate
well in culture and re-enter cell cycle after serum starvation
without significant delay (Ortega et al., 2003). Presumably, ab-
lation of Cdk2 is compensated by other Cdks. However, Cdk2
is essential for the first meiotic division of both male and female
germ cells, an activity that cannot be compensated by any
other kinase (Ortega et al., 2003). These findings have raised
questions regarding other proposed roles for Cdk2 based on
biochemical or cell biology studies. One such proposed role
involves mediation of the cell cycle inhibitory and tumor sup-
pressor activities of p27Kip1 and p21Cip1.
In this study, we report that overexpression of p27Kip1 and
p21Cip1 induces cell cycle arrest in the absence of Cdk2. More-
over, none of the deficiencies analyzed in p27Kip1−/− and
p21Cip1−/− cells is reversed by deletion of Cdk2. Perhaps more
importantly, ablation of Cdk2 does not reverse organomegalia
in p27Kip1−/− mice, nor prevent development of pituitary tu-
mors. These results provide genetic evidence that Cdk2 is not
an essential target for p21Cip1 or p27Kip1. Moreover, they raise
a note of caution regarding the suitability of Cdk2 as a target
for therapeutic intervention, at least in those tumors lacking
Cip/Kip tumor suppressors.
Results
p27Kip1 and p21Cip1 block cell cycle progression
in the absence of Cdk2
To investigate whether Cip/Kip inhibitors cause cell cycle arrest
in the absence of Cdk2, early-passage Cdk2+/+ and Cdk2−/−
mouse embryonic fibroblasts (MEFs) were infected with retro-592Figure 1. Ectopic expression of p27Kip1 and p21Cip1 arrests cell cycle pro-
gression in wild-type and Cdk2-deficient cells
A: Expression levels of p27Kip1 and p21Cip1 in Cdk2+/+ and Cdk2−/− primary
MEFs after retroviral infection with either empty virus (M) or with viruses en-
coding p27Kip1 or p21Cip1 proteins. Expression of the Erk protein was used
as loading control. Migration of the proteins is indicated by arrowheads.
B: Growth curves of Cdk2+/+ (open symbols) and Cdk2−/− (filled symbols)
primary MEFs after retroviral infection with either empty virus (circles) or
with viruses encoding p27Kip1 (triangles) or p21Cip1 (squares).
C: DNA content of Cdk2+/+ or Cdk2−/− MEFs after infection with either empty
virus (mock) or with a retrovirus encoding p27Kip1. The percentage of cells
in G1 (open bars), S (gray bars), or G2/M (solid bars) phases of the cell
cycle is indicated. The means ± SD for 6 different embryos per genotype
and 3 different experiments are shown.viruses expressing p27Kip1 or p21Cip1 (Figure 1A). Ectopic ex-
pression of p27Kip1 or p21Cip1 halted the proliferation of these
primary MEFs regardless of the presence or absence of Cdk2
(Figure 1B). As expected, p27Kip1 induced cell cycle arrest in
both G1 and G2/M, presumably by inhibiting the kinase activity
of Cdk2 bound to cyclin E and cyclin A, respectively (Figure
1C). Surprisingly, p27Kip1 also blocked cell cycle progression in
G1 (58% of the cells) and G2/M (42%) in the absence of Cdk2.
It could be hypothesized that cell cycle arrest in G2/M may
be mediated by Cdk1, a known target of p27Kip1 (reviewed in
Pagano, 2004). However, the mechanism by which p27Kip1 in-
duces cell cycle arrest in G1 in Cdk2−/− cells is less obvious.
To investigate the effect of expressing p27Kip1 or p21Cip1 on
various Cdk-cyclin complexes in the absence of Cdk2, we as-
sayed their kinase activity present in the corresponding immu-
noprecipitates derived from Cdk2+/+ and Cdk2−/− MEFs (Figure
2). As expected, whereas Cdk2 kinase activity was dramatically
decreased in wild-type cells, ectopic expression of p27Kip1 or
p21Cip1 had no effect on Cdk4 kinase, at least as determinedCANCER CELL : JUNE 2005
A R T I C L EFigure 2. Expression levels and protein kinase activity of Cdk2, Cdk4, Cdk1,
cyclin E, and cyclin A immunoprecipitates obtained from Cdk2+/+ and
Cdk2−/− MEFs ectopically expressing p27Kip1 or p21Cip1 proteins
Cell extracts obtained from Cdk2+/+ and Cdk2−/− MEFs either mock in-
fected or infected with retroviruses expressing p21Cip1 or p27Kip1 proteins
were incubated with antibodies against Cdk2, Cdk4, Cdk1, cyclin E, and
cyclin A, and the resulting immunoprecipitates assayed for kinase activity
using histone H1 (H1 kinase) or a fragment of the retinoblastoma protein
(Rb kinase) as substrates. Cell extracts were analyzed by Western blot with
the same antibodies to determine the levels of expression of each of the
above Cdks and cyclins. Results are depicted immediately below the cor-
responding kinase assay. The migration of the Cdks, cyclins, and phosphor-
ylated substrates H1-P and pRb-P is indicated by arrowheads. A Western
blot using β-actin antibodies was used as a loading control.by its ability to phosphorylate pRb (Figure 2 and Supplemental
Data). In agreement with previous studies, ectopic expression
of p27Kip1 or p21Cip1 significantly reduced Cdk1 kinase activity
in wild-type MEFs (Toyoshima and Hunter, 1994; Harper et al.,
1995). In Cdk2−/− MEFs, Cdk1 kinase activity was completely
inhibited upon p27Kip1 or p21Cip1 expression, a result that may
account for the fraction of Cdk2−/− cells arrested in G2/M (Fig-
ure 1C) (Pagano, 2004). It should be noted that Cdk1 kinase
activity was reduced in cells lacking Cdk2, most likely a conse-
quence of the lower levels of Cdk1 expression in Cdk2 null
cells (Ortega et al., 2003). Cyclin E-associated kinase activity,
presumably mediated by Cdk2, was also inhibited by p27Kip1
or p21Cip1 expression regardless of whether we used histone
H1 or pRB protein as a substrate (see Figure 2 and Supple-
mental Data). No cyclin E associated kinase activity could be
observed in immunoprecipitates obtained from Cdk2−/− cells,
regardless of the expression of p27Kip1 or p21Cip1 (Ortega et
al., 2003). In agreement with previous studies (Ortega et al.,
2003; Berthet et al., 2003), Cyclin A-associated kinase activity
is greatly decreased in Cdk2 null cells (Figure 2). This residual
activity, presumably mediated by Cdk1-cyclin A complexes,CANCER CELL : JUNE 2005was completely eliminated upon expression of p27Kip1 or
p21Cip1 (Figure 2), thus providing further support to the con-
cept that these inhibitors also block Cdk1 kinase activity.
Biological activity of mutant p27Kip1 and p21Cip1 proteins
is independent of Cdk2
To determine whether binding of p27Kip1 to Cdk-cyclin com-
plexes is required for its cell cycle inhibitory properties in Cdk2
null cells, we generated two p27Kip1 mutants, p27Kip1 F64A and
p27Kip13M. p27Kip1F64A has a single F64A mutation that re-
duces binding to the Cdk catalytic subunit (Kwon and Nordin,
1998). p27Kip13M carries two additional mutations (L32H;P35A)
within a putative cyclin binding motif based on sequence ho-
mology with p21Cip1 (Lin et al., 1996). Thus, p27Kip13M should
not be able to bind either Cdk or cyclin subunits. As illustrated
in Figure 3A, the p27Kip1F64A mutant binds to all Cdk and
cyclin subunits examined with an efficiency similar to that of
the wild-type protein. Whether recognition of the catalytic sub-
units Cdk1, Cdk2, and Cdk4 was mediated by binding to their
cognate cyclins was not examined. In contrast, the triple mu-
tant, p27Kip13M, was not able to recognize any Cdk-cyclin
complexes as determined by immunoprecipitation assays (Fig-
ure 3B). Next, we examined whether these mutant p27Kip1 pro-
teins retained cell cycle inhibitory properties. As illustrated in
Figure 3C, p27Kip1F64A was almost as efficient as the wild-
type protein in blocking cell cycle progression as determined
by BrdU incorporation. Its inhibitory activity was the same in
Cdk2+/+ and Cdk2−/− MEFs. In contrast, p27Kip13M completely
lost its ability to inhibit BrdU incorporation in both wild-type
and Cdk2−/− MEFs. These observations indicate a strong corre-
lation between cell cycle inhibitory activity of p27Kip1 and its
ability to interact with Cdk-cyclin complexes, regardless of the
presence or absence of Cdk2.
In addition to Cdk-cyclin complexes, p21Cip1 also binds to
PCNA, preventing its interaction with the catalytic subunit of
DNA polymerase delta, an enzyme required for DNA replication
(Luo et al., 1995; Chen et al., 1995). Expression of p21Cip1, a
mutant p21Cip1 protein that cannot bind to PCNA (Cayrol et al.,
1998), also caused cell cycle arrest in MEFs regardless of Cdk2
expression (see Supplemental Data). These results suggest
that PCNA is not a major target for p21Cip1, at least in MEFs.
Loss of Cdk2 does not suppress the proliferative
advantages of cells lacking p27Kip1 and p21Cip1
To provide genetic evidence for a possible epistatic interaction
between Cip/Kip inhibitors and Cdk2, we examined the conse-
quences of ablating Cdk2 in cells defective for either p27Kip1
or p21Cip1. Double knockout p27Kip1−/−;Cdk2−/− and p21Cip1−/−;
Cdk2−/− mice were born at the expected Mendelian ratio and
did not display any defects other than those previously re-
ported for their parental single knockout animals. Primary
p27Kip1−/−;Cdk2−/− and p21Cip1−/−;Cdk2−/− MEFs, isolated from
mid-gestation embryos, displayed increased proliferation rates
similar to those of p27Kip1 null or p21Cip1 null cells (Figure 4A),
thus indicating that loss of Cdk2 does not abrogate the prolifer-
ative advantage conferred by the absence of p27Kip1 or
p21Cip1. Similar results were obtained in colony formation as-
says. For instance, whereas we scored 25 ± 14 colonies after
seeding 3,000 wild-type cells, p21Cip1−/− MEFs yielded 114 ±
16 colonies, a figure very similar to that obtained in the corre-
sponding MEFs lacking both p21Cip1 and Cdk2 (118 ± 13 colo-593
A R T I C L EFigure 3. Cell cycle inhibitory properties of mutant p27Kip1 proteins
A: Cdk2+/+ and Cdk2−/− MEFs infected with empty retrovirus (mock) or with
viruses expressing Flag-tagged wild-type p27Kip1 or mutated p27Kip1F64A
proteins.
B: Cdk2+/+ and Cdk2−/− MEFs infected with empty retrovirus (mock) or with
viruses expressing Flag-tagged wild-type p27Kip1 or mutated p27Kip13M pro-
teins. p27Kip1 complexes were immunoprecipitated using anti-Flag anti-
bodies, and the levels of the indicated proteins, including Cdk2, Cdk4,
Cdk1, cyclin D2, cyclin E, and p27Kip1, were detected by Western blot
analysis using the corresponding antibodies. Migration of these proteins is
indicated by arrowheads.
C: BrdU incorporation (expressed as percentage of positive cells) in Cdk2+/+
and Cdk2−/− immortal MEFs either mock infected (Mock; filled bars) or in-
fected with retroviruses encoding Flag-tagged p27Kip1 wild-type (p27Kip1;
open bars) or mutated Fg-p27Kip1F64A (F64A; light gray bars) and Fg-
p27Kip13M (3M; dark gray bars) proteins. The average value of two different
clones per genotype is represented. At least two different experiments
were performed with all the cell lines.594Figure 4. Ablation of Cdk2 does not affect the proliferative properties of
cells lacking p27Kip1 or p21Cip1 inhibitors
A: Proliferation rates of primary MEFs deficient in p27Kip1 (triangles) or
p21Cip1 (squares) in the presence (closed symbols) or absence (open sym-
bols) of Cdk2. Curves depicting the proliferation rates of wild-type (closed
circles) and Cdk2−/− (open circles) primary MEFs are also indicated by dot-
ted lines.
B: Kinetic analysis of S phase entry of primary MEFs deficient in p27Kip1 or
p21Cip1 in the presence or absence of Cdk2. Kinetics of S phase entry of
wild-type and Cdk2 primary MEFs are also indicated. Symbols are those
indicated in A.nies). Finally, quiescent p27Kip1 and p21Cip1 deficient MEFs en-
ter S phase 4 to 6 hr earlier than wild-type cells upon serum
stimulation, a differential effect also observed in primary
p27Kip1−/−;Cdk2−/− and p21Cip1−/−;Cdk2−/− MEFs (Figure 4B),
suggesting that the shortening in S phase entry is not mediated
by constitutively active Cdk2.
Cdk2 is not essential for p21Cip1-mediated cell cycle
arrest after DNA damage
p21Cip1 is one of the major effectors of cell cycle arrest induced
upon DNA damage (Deng et al., 1995; Brugarolas et al., 1995).
To examine the contribution of Cdk2 to these DNA damage
checkpoints, we exposed wild-type, Cdk2−/−, p21Cip1−/−, and
p21Cip1−/−;Cdk2−/− primary MEFs to γ irradiation or to etopo-
side. Serum-starved cells were irradiated in suspension using
a single dose of 10 Gy and stimulated with 10% of serum to
reenter the cell cycle. BrdU was added to allow detection of
cells entering S phase. Irradiated wild-type and Cdk2−/− MEFs
showed a 60% reduction in the number of BrdU-positive cells
and a concomitant 10%–15% increase in the G1 population
relative to nonirradiated samples (Figure 5A). Ablation of
p21Cip1 resulted in impaired checkpoint arrest, since p21Cip1
null cells maintained high levels of BrdU incorporation and
lacked G1 arrest. As illustrated in Figure 5A, double mutant
p21Cip1−/−;Cdk2−/− cells also displayed increased BrdU incor-CANCER CELL : JUNE 2005
A R T I C L EFigure 5. DNA damage checkpoint in MEFs exposed to γ radiation and eto-
poside
A: Percentage of cells either untreated (U) or exposed (T) to γ radiation in
G1 (open bars), S (gray bars), or G2/M (filled bars) phases of the cell cycle.
The corresponding genotype of each of the treated cells is indicated.
B: As above except that cells were treated with etoposide.poration and failed to arrest in G1. Similar results were ob-
tained using etoposide, another DNA damaging agent (Figure
5B). Whereas wild-type cells arrested both in G1 and G2/M,
p21Cip1 null cells treated with etoposide were not able to arrest
in G1, and most of them accumulated in G2/M. As illustrated
in Figure 5B, this effect was also independent of Cdk2. These
observations provide genetic evidence against the concept
that p21Cip1 mediates cell cycle arrest at the DNA damage
checkpoint by blocking Cdk2 activity.
Cip/Kip tumor suppressor activity does not require Cdk2
p27Kip1 and p21Cip1-deficient MEFs show slightly increased
susceptibility to cellular transformation in vitro. Ectopic expres-
sion of Ras and E1A oncogenes induced significantly more foci
of transformed cells in either p27Kip1 and p21Cip1 null MEFs
than in wild-type cells. Whereas we scored 17 ± 8 foci in wild-
type cells, we observed 20 ± 7 and 33 ± 7 in p27Kip1 and
p21Cip1 null MEFs, respectively. When similar experiments
were carried out using primary MEFs lacking Cdk2, results
were essentially identical. That is, we observed 23 ± 9 foci in
p27Kip1−/−;Cdk2−/− cells, and 27 ± 5 foci in p21Cip1−/−;Cdk2−/−
MEFs, respectively. These observations suggest that the in-
creased susceptibility to transformation by Ras and E1A onco-
genes of Cip/Kip deficient cells is not due to increased Cdk2
activity.
To examine the genetic interactions between Cdk2 and Cip/CANCER CELL : JUNE 2005Kip inhibitors in vivo, we analyzed the phenotype of mice defi-
cient for Cdk2 and p27Kip1. Ablation of p27Kip1 in mice results
in hyperplasia leading to generalized organomegaly and in-
creased body size. Moreover, these animals develop retinal
dysplasia and pituitary tumors of the intermediate lobe (Naka-
yama et al., 1996; Kiyokawa et al., 1996; Fero et al., 1996).
p27Kip1−/−;Cdk2−/− double mutant mice weighted 50% to 60%
more than wild-type and Cdk2−/− mice and displayed wide-
spread organomegalia, similar to p27Kip1−/− animals (Figure 6).
Testes and ovaries of p27Kip1−/−;Cdk2−/− mutant mice also dis-
played reduced size similar to those of Cdk2 null mice (data not
shown). Close examination of these tissues revealed complete
absence of germ cells as well as an atrophic architecture indis-
tinguishable from that of Cdk2−/− single mutant mice (Ortega
et al., 2003) (data not shown). These observations indicate that
the meiotic defects that result from ablation of Cdk2 are inde-
pendent of p27Kip1.
p27Kip1−/−;Cdk2−/− mice displayed the same retinal defects
observed in p27Kip1 null mice and with similar low penetrance
(about 10%) (Nakayama et al., 1996; Kiyokawa et al., 1996).
These defects involve partial invasion of the rods and cones
layer by the outer granular layer (Figure 7A). More importantly,
these double mutant mice develop pituitary tumors with the
same penetrance and latency as p27Kip1 single mutant ani-
mals. As illustrated in Figure 7B, 10-week-old p27Kip1−/− (n =
3) and p27Kip1−/−;Cdk2−/−mice (n = 3) displayed similar hyper-
plastic pituitary glands. Moreover, all p27Kip1−/− (n = 6) and
p27Kip1−/−;Cdk2−/− (n = 6), but not Cdk2−/− (n = 6), mice hadFigure 6. Loss of Cdk2 does not abrogate organomegalia of p27
Kip1
null
mice
A: Mice lacking p27Kip1 have larger size regardless of the presence or ab-
sence of Cdk2. The genotypes of the representative mice depicted in this
photograph are indicated.
B: Total body weight (Bo) and weight of individual organs, including spleen
(Sp), kidney (Kd), liver (Li), thymus (Th), heart (Hr), and brain (Br) of Cdk2−/−
(open bars), p27
Kip1−/−
(black bars), and p27
Kip1−/−
;Cdk2−/− (gray bars) mice
relative to the corresponding weights of wild-type mice. The means ± SD
for 3 different animals from each genotype are shown.595
A R T I C L EFigure 7. Loss of Cdk2 does not suppress the tumor suppressor properties
of p27Kip1
A: H&E staining of sections of normal retinas obtained from p27
Kip1+/+
;
Cdk2+/+ mice and of retinas obtained from p27
Kip1−/−
;Cdk2+/+ and p27
Kip1−/−
;
Cdk2−/− mice displaying the invasion of the rod and cone layer (arrow-
heads) by the outer granular layer.
B: Upper row: 10-week-old mice. Photographs of normal pituitary glands
obtained from p27
Kip1+/+
;Cdk2+/+ mice and hyperplastic glands observed
in p27
Kip1−/−
;Cdk2+/+ and p27
Kip1−/−
;Cdk2−/− animals. Lower row: 24-week-
old mice. H&E staining of sections of normal pituitary glands obtained from
p27
Kip1+/+
;Cdk2+/+ mice and from pituitary tumors that developed in
p27
Kip1−/−
;Cdk2+/+ and p27
Kip1−/−
;Cdk2−/− double mutant mice.
C: Percentage of Ki67-positive cells and size of pituitary glands from 24-
week-old p27
Kip1+/+
;Cdk2+/+ (filled bars), p27
Kip1−/−
;Cdk2+/+ (open bars),
and p27
Kip1−/−
;Cdk2−/− (gray bars) mice. All pituitary glands examined from
p27
Kip1−/−
;Cdk2+/+ and p27
Kip1−/−
;Cdk2−/− mice were neoplastic. Pituitary
sections derived from five 6 month-old mice were analyzed. At least 3 dif-
ferent fields per section were counted and the resulting means ± SD are
represented.pituitary tumors at six months of age (Figure 7B). These pitu-
itary tumors display similar elevated proliferative indexes and
volumes in p27Kip1−/− and p27Kip1−/−;Cdk2−/− double mutant
mice (Figure 7C). These results illustrate that Cdk2 does not596play a significant role in mediating the in vivo tumor suppressor
activity of p27Kip1.
Discussion
We and others have recently demonstrated that Cdk2 is not
essential for the mitotic cell cycle in mammalian cells (Ortega
et al., 2003; Berthet et al., 2003). Now, we describe results that
establish that Cdk2 is not essential for mediating either the cell
cycle inhibitory or the tumor suppressing properties of p27Kip1
and p21Cip1. Moreover, our results argue against an epistatic
relationship between these Cip/Kip inhibitors and Cdk2, thus
challenging one of the most widely established steps in the
progression from the G1 to the S phase of the cell cycle.
Our findings illustrate that p27Kip1and p21Cip1 can inhibit cell
cycle progression in cells that lack Cdk2. These observations
suggest either that Cdk2 is not the primary target of Cip/Kip
inhibitors in vivo, or, alternatively, that p27Kip1and p21Cip1 can
block cell cycle progression by interacting with molecules
other than Cdk2. Assuming the latter, the most likely compen-
satory molecules would be the Cdks involved in cell cycle pro-
gression, mainly Cdk1, Cdk3, Cdk4, and Cdk6. In fact, p27Kip1
mutant proteins defective in Cdk and cyclin binding are not
effective in blocking cell cycle in Cdk2 null cells.
Cdk4 and Cdk6 are unlikely mediators of the cell cycle inhibi-
tory properties of p27Kip1and p21Cip1, since it has been well
illustrated that these inhibitors do not block the kinase activity
of Cdk4/6-cyclin D complexes. Instead, increasing evidence
supports the concept that Cip/Kip inhibitors help to stabilize
Cdk4/6-cyclin D complexes (Blain et al., 1997; LaBaer et al.,
1997; Cheng et al., 1999). Recent genetic evidence also argues
against a compensatory role of Cdk4 and Cdk6 in mediating
p27Kip1and p21Cip1 activities, since both of these molecules
effectively block cell proliferation in MEFs lacking either Cdk4
and Cdk6, or the three D type cyclins (Malumbres et al., 2004;
Kozar et al., 2004). Thus, it is unlikely that Cdk4 and Cdk6
mediate cell cycle inhibition by Cip/Kip inhibitors. On the other
hand, we have recently shown, using shRNA strategies, that
Cdk2 partially compensates for the absence of Cdk4 and Cdk6
in MEFs, most likely by a mechanism involving its interaction
with D type cyclins (Malumbres et al., 2004). Thus, it is possible
that if in cells lacking Cdk4 and Cdk6, Cdk2-cyclin D com-
plexes are responsible for driving cells through G1, p27Kip1 and
p21Cip1 may block cell cycle progression by inhibiting Cdk2-
cyclin D kinase activity. Yet, this hypothesis would not explain
how p27Kip1 and p21Cip1 inhibit the cell cycle in the absence
of Cdk2.
Cdk3, a Cdk2-related kinase recently implicated in the G0/
G1 transition (Ren and Rollins, 2004), is unlikely to serve as a
compensatory molecule for Cdk2, since it is not functional in
all the cells and mice used in this study (data not shown) due
to a naturally occurring mutation in the cdk3 locus of most lab-
oratory strains of mice (Ye et al., 2001).
Cdk1 is also a candidate to compensate for the absence of
Cdk2, since p27Kip1 and p21Cip1 bind to Cdk1 and inhibit its
kinase activity (Toyoshima and Hunter, 1994; Harper et al.,
1995), thus making Cdk1 a potential candidate to compensate
for the absence of Cdk2. In agreement with these observa-
tions, we have detected p27Kip1 and p21Cip1 binding to Cdk1
and inhibition of its kinase activity in both wild-type and Cdk2-
deficient cells (Figure 2). Moreover, a significant percentage ofCANCER CELL : JUNE 2005
A R T I C L ECdk2-deficient cells arrest in the G2/M phase of the cell cycle
upon ectopic expression of p27Kip1, thus suggesting that Cdk1
mediates at least some of the properties of these inhibitors in
the absence of Cdk2. This hypothesis is supported by recent
results demonstrating that ablation of p27Kip1 suppresses en-
doreplication of Skp2-deficient hepatocytes, an observation at-
tributed to inhibition of Cdk1 by increased expression of
p27Kip1 during the S/G2 transition (Nakayama et al., 2004).
However, these observations do not explain how p27Kip1 and
p21Cip1 effectively block cell cycle progression in G1 in the ab-
sence of Cdk2. Indeed, if we postulate that Cdk1 mediates all
the cell cycle inhibitory activity of p27Kip1 and p21Cip1 in the
absence of Cdk2, such a hypothesis would imply that Cdk1
must participate in driving the G1/S transition, a possibility that
deserves further examination. To date, we have not been able
to obtain Cdk1-deficient MEFs, since mice lacking this kinase
die during the very early stages of embryonic development (our
unpublished observations). Whether generation of Cdk1 condi-
tional mutant cells or even shRNA approaches would help to
resolve this issue remains to be determined.
Regardless of the molecular mechanisms responsible for the
activity of p27Kip1 in cells lacking Cdk2, we find it remarkable
that ablation of Cdk2 did not revert any of the phenotypes in-
duced by loss of this tumor suppressor. These observations
suggest either that Cdk2 may not be a physiological target of
p27Kip1 or that mice may have additional targets equally re-
sponsible for mediating the tumor suppressor properties of
p27Kip1 (Pagano, 2004). These findings are in sharp contrast
with those recently reported for mice deficient for p27Kip1 and
Skp2 (Nakayama et al., 2004). Concomitant ablation of these
molecules restores most of the defects observed in p27Kip1 null
animals, thus establishing an epistatic relationship between
p27Kip1 and Skp2, the F box protein responsible for its degra-
dation (Nakayama et al., 2004).
Loss of p27Kip1 expression is a common feature of many
human cancers, an event frequently associated with poor
prognosis (reviewed in Bloom and Pagano, 2003; Blain et al.,
2003; Malumbres and Carnero, 2003). Likewise, a large fraction
of human neoplasias carry mutations in the p53 pathway that
prevent expression of p21Cip1 (reviewed in Lowe et al., 2004;
Vousden and Prives, 2005). Although we realize that Cdk2 inhi-
bition by selective inhibitors might have different effects than
eliminating the Cdk2 protein, our findings raise a note of cau-
tion regarding the suitability of Cdk2 as a target for therapeutic
intervention, at least in tumors lacking p27Kip1 or p21Cip1 ex-
pression. In any case, the results reported here should stimu-
late further work to identify essential mediator(s) of the tumor
suppressor properties of the p27Kip1 and p21Cip1 cell cycle in-
hibitors.
Experimental procedures
Mice and tissues
p27Kip1−/−, p21Cip1−/−, and Cdk2−/− mice have been described (Brugarolas
et al., 1995; Kiyokawa et al., 1996; Ortega et al., 2003). Tissue samples
were fixed in formalin for 24 hr and embedded in paraffin, and 3 m sec-
tions were analyzed after staining with hematoxylin and eosin (H&E). For
proliferation studies, tissues were stained with Ki67-specific antibodies
(Dako). All experiments involving mice were performed in accordance with
institutional guidelines (CNIO Committee for the Use and Care of Experi-
mental Animals) and the corresponding national regulations.CANCER CELL : JUNE 2005Cell culture
Primary MEFs were obtained from E13.5 embryos as reported (Ortega et
al., 2003). For cell proliferation assays, we plated 5 × 104 cells on six-well
plates and counted daily for 4 days. For S phase assays, P2 MEFs (106
cells per 10 cm dish) were placed in DMEM containing 0.1% FBS for 60 hr.
Cells were restimulated by addition of 10% FBS. 50 M of BrdU was added
1 hr before harvesting at the indicated time points. DNA content was ana-
lyzed by flow cytometry (Coulter XL or FACScan from Becton-Dickinson).
Focus formation assays were performed as described (Sotillo et al., 2001).
For γ irradiation, MEFs were trypsinized and suspended in growth medium
before irradiation at room temperature with a dose of 10 Gy. Cells were
replated in growth medium at 40%–60% confluence. The percentage of
cells in S phase was determined by flow cytometric analysis and by BrdU
incorporation. For etoposide treatment, MEFs were grown in the presence
of 5 M etoposide for 24 hr and collected 1 day later. Cell cycle profile was
also determined using flow cytometry. For expression of p27Kip1 or p21Cip1,
phoenix cells were transfected with 6 g of ecotropic helper retrovirus plas-
mid (pCL-Eco) plus 6 g of pBabe vector encoding the corresponding pro-
teins. The p21Cip1 mutant cDNA defective for PCNA binding (p21Cip1) was
described previously (Cayrol et al., 1998). A Flag-tagged p27Kip1 cDNA was
modified using in vitro mutagenesis (Stratagene) to obtain two cDNAs en-
coding a single (F64A) and a triple (L32H;P35A;F64A) mutant designated as
p27Kip1F64A and p27Kip13M, respectively (Lin et al., 1996; Kwon and Nor-
din, 1998). Supernatants were used to infect primary MEFs as described
(Cheng et al., 1999). Cells were placed under puromycin selection and har-
vested 2–3 days later.
Western blot, immunoprecipitation, and kinase assays
Protein isolation and analysis was performed as described (Ortega et al.,
2003). Protein extracts were immunoprecipitated by using antibodies
against Flag (Sigma), Cdk1, Cdk2, Cdk4, cyclin E, or cyclin A (Santa Cruz
Biotechnology). For Western blot analysis, protein lysates were transferred
to nitrocellulose membranes and probed with antibodies against Cdk2,
Cdk1, Cdk4, p21Cip1, cyclin E, cyclin A, cyclin D2, or ERK (Santa Cruz Bio-
technology), p27Kip1 (Transduction Laboratories), or β-actin (Sigma). For ki-
nase assays, we used 1 g of mouse pRb protein fragment (amino acids
769–921; Santa Cruz Biotechnology) or histone H1 (Roche) as substrates.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/6/591/DC1/.
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